Back to top
more

Ocuphire Pharma (OCUP)

(Delayed Data from NSDQ)

$1.72 USD

1.72
456,165

-0.24 (-12.24%)

Updated May 10, 2024 04:00 PM ET

After-Market: $1.70 -0.02 (-1.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ocuphire Pharma, Inc. (OCUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up

by Zacks Equity Research

Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Ocuphire Pharma, Inc. (OCUP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Ocuphire Pharma, Inc. (OCUP) closed at $5.86, marking a +0.86% move from the previous day.

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

by Zacks Equity Research

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance

by Zacks Equity Research

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.

Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Ocuphire Pharma, Inc. (OCUP) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.

Ocuphire Pharma, Inc. (OCUP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Ocuphire Pharma, Inc. (OCUP) closed at $5.36 in the latest trading session, marking a -0.56% move from the prior day.

Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Ocuphire Pharma, Inc. (OCUP) points to a 323.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Indrajit Bandyopadhyay headshot

4 Medical Stocks to Buy as Rate Hike Cycle Nears End

by Indrajit Bandyopadhyay

We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.

Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep going

by Zacks Equity Research

Ocuphire Pharma, Inc. (OCUP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?